At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Market Closed 12-05 16:00:00 EST
26.72
-1.18
-4.23%
盘后26.72
+0.000.00%
19:56 EST
High28.11Low26.65Vol396.63K
Open27.70D1 Closing27.90Amplitude5.22%
Mkt Cap836.07MTradable Cap419.30MTotal Shares31.29M
T/O10.79MT/O Rate2.53%Tradable Shares15.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
GlobeNewswire  ·  12-07 06:30
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire  ·  12-06 21:00
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Spyre Therapeutics Announces Grants of Inducement Awards
GlobeNewswire  ·  12-06 05:05
Spyre Therapeutics Announces Grants of Inducement Awards
Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating
MT Newswires Live  ·  12-05 21:34
Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating
Neuphoria Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  12-05 21:05
Neuphoria Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Morgan Stanley Initiates BridgeBio Oncology Therapeutics With Overweight Rating, $20 Price Target
MT Newswires Live  ·  12-05 20:44
Morgan Stanley Initiates BridgeBio Oncology Therapeutics With Overweight Rating, $20 Price Target
Denali Therapeutics Price Target Maintained With a $32.00/Share by BTIG
Dow Jones  ·  12-05 18:48
Denali Therapeutics Price Target Maintained With a $32.00/Share by BTIG
Press Release: OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
Dow Jones  ·  12-05 18:29
Press Release: OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound
Simply Wall St.  ·  12-05 12:42
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
GlobeNewswire  ·  12-05 09:00
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
Protara Therapeutics Launches Offering of Securities
MT Newswires Live  ·  12-05 06:45
Protara Therapeutics Launches Offering of Securities
Press Release: Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
Dow Jones  ·  12-04
Press Release: Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment
Dow Jones  ·  12-04
Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment
Trevi Therapeutics Names David Hastings CFO
MT Newswires Live  ·  12-04
Trevi Therapeutics Names David Hastings CFO
Stifel Nicolaus Initiates Coverage on Tango Therapeutics With Buy Rating, $15 Price Target
MT Newswires Live  ·  12-04
Stifel Nicolaus Initiates Coverage on Tango Therapeutics With Buy Rating, $15 Price Target
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
GlobeNewswire  ·  12-04
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
Press Release: Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
Dow Jones  ·  12-04
Press Release: Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
GlobeNewswire  ·  12-04
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
GlobeNewswire  ·  12-04
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
Addex Therapeutics Q3 EPS $(1.50) Up From $(2.77) YoY, Sales $62.500K Down From $68.161K YoY
Benzinga  ·  12-04
Addex Therapeutics Q3 EPS $(1.50) Up From $(2.77) YoY, Sales $62.500K Down From $68.161K YoY

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--